AVS, a Boston, MA-based medical device company, raised additional $8.8M in Series B funding.
The round, which brought the total amount of its Series B to $28.8M, was led by BioStar Capital with CUE Growth Partners.
The company intends to use the funds to support clinical trials for its device for pulsatile intravascular lithotripsy (PIVL) in peripheral cases, while advancing preclinical work for an expanded indication in coronary cases.
Founded in 2018 by Hitinder Gurm and Robert Chisena, AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It works for the interventional therapy for severely calcified lesions with the Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device.
FinSMEs
05/04/2023